Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients ; volume:23 ; number:1 ; day:1 ; month:11 ; year:2022 ; pages:1-12 ; date:12.2022
The journal of headache and pain ; 23, Heft 1 (1.11.2022), 1-12, 12.2022
- Urheber
-
Barbanti, Piero
Egeo, Gabriella
Aurilia, Cinzia
Altamura, Claudia
d’Onofrio, Florindo
Finocchi, Cinzia
Albanese, Maria
Aguggia, Marco
Rao, Renata
Zucco, Maurizio
Frediani, Fabio
Filippi, Massimo
Messina, Roberta
Cevoli, Sabina
Carnevale, Antonio
Fiorentini, Giulia
Messina, Stefano
Bono, Francesco
Torelli, Paola
Proietti, Stefania
Bonassi, Stefano
Vernieri, Fabrizio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-022-01498-6
- URN
-
urn:nbn:de:101:1-2023011621021232445311
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Barbanti, Piero
- Egeo, Gabriella
- Aurilia, Cinzia
- Altamura, Claudia
- d’Onofrio, Florindo
- Finocchi, Cinzia
- Albanese, Maria
- Aguggia, Marco
- Rao, Renata
- Zucco, Maurizio
- Frediani, Fabio
- Filippi, Massimo
- Messina, Roberta
- Cevoli, Sabina
- Carnevale, Antonio
- Fiorentini, Giulia
- Messina, Stefano
- Bono, Francesco
- Torelli, Paola
- Proietti, Stefania
- Bonassi, Stefano
- Vernieri, Fabrizio
- SpringerLink (Online service)
Ähnliche Objekte (12)
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy